Buprederm™, a New Transdermal Delivery System of Buprenorphine: Pharmacokinetic, Efficacy and Skin Irritancy Studies

Purpose The pharmacokinetics, analgesic efficacy, and irritancy potential of Buprederm™, a new transdermal delivery system of buprenorphine, was evaluated. Methods Single and multiple dose pharmacokinetic studies were conducted in mice and rabbits. The analgesic efficacy and skin irritation potential were determined by tail flick and writhing tests in mice and by the Draize dermal scoring system in rabbits. Results Fast absorption of buprenorphine into the bloodstream was observed in mice and rabbits after Buprederm™ application. The peak buprenorphine level in plasma was achieved between 1 and 24 h, and the effective therapeutic drug concentration was maintained for 72 h. No significant accumulation of buprenorphine was seen after multiple consecutive applications of patches to rabbits with a 4-day dosing interval. Buprederm™ induced prolongation of tail-flick latency in a dose- and time-dependent manner. Maximum analgesic effect was attained between 3 and 6 h and was maintained for 24 h after patch application. No skin irritation was demonstrated in rabbits after repeated Buprederm™ application. Conclusions Buprederm™ was shown to be efficacious by achieving the effective buprenorphine concentration in the blood and brain sufficient to maintain an analgesic effect for 72 h, and was also shown to be safe following multiple applications.